Literature DB >> 22344702

Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Hsia-Lien Lin1, Cesar Kenaan, Paul F Hollenberg.   

Abstract

Previous studies have demonstrated that bergamottin (BG), a component of grapefruit juice, is a mechanism-based inactivator of CYP3A4 and contributes, in part, to the grapefruit juice-drug interaction. Although the covalent binding of [(14)C]BG to the CYP3A4 apoprotein has been demonstrated by SDS-polyacrylamide gel electrophoresis, the identity of the modified amino acid residue and the reactive intermediate species of BG responsible for the inactivation have not been reported. In the present study, we show that inactivation of CYP3A4 by BG results in formation of a modified apoprotein-3A4 and a GSH conjugate, both exhibiting mass increases of 388 Da, which corresponds to the mass of 6',7'-dihydroxybergamottin (DHBG), a metabolite of BG, plus one oxygen atom. To identify the adducted residue, BG-inactivated 3A4 was digested with trypsin, and the digests were then analyzed by liquid chromatography-tandem mass spectrometry (MS/MS). A mass shift of 388 Da was used for the SEQUEST database search, which revealed a mass increase of 388 Da for the peptide with the sequence (272)LQLMIDSQNSK(282), and MS/MS analysis of the adducted peptide demonstrated that Gln273 is the residue modified. Mutagenesis studies showed that the Gln273 to Val mutant was resistant to inactivation by BG and DHBG and did not generate two of the major metabolites of BG formed by 3A4 wild type. In conclusion, we have determined that the reactive intermediate, oxygenated DHBG, covalently binds to Gln273 and thereby contributes to the mechanism-based inactivation of CYP3A4 by BG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344702      PMCID: PMC3336797          DOI: 10.1124/dmd.112.044560

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  33 in total

1.  Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients.

Authors:  D G Bailey; G K Dresser; J H Kreeft; C Munoz; D J Freeman; J R Bend
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

3.  Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity.

Authors:  L Q Guo; K Fukuda; T Ohta; Y Yamazoe
Journal:  Drug Metab Dispos       Date:  2000-07       Impact factor: 3.922

4.  Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.

Authors:  A Ohnishi; H Matsuo; S Yamada; H Takanaga; S Morimoto; Y Shoyama; H Ohtani; Y Sawada
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 5.  Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes.

Authors:  Haoming Zhang; Hsia-lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Arch Biochem Biophys       Date:  2010-09-15       Impact factor: 4.013

6.  Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.

Authors:  L K Lightning; J P Jones; T Friedberg; M P Pritchard; M Shou; T H Rushmore; W F Trager
Journal:  Biochemistry       Date:  2000-04-18       Impact factor: 3.162

7.  Inhibition selectivity of grapefruit juice components on human cytochromes P450.

Authors:  W Tassaneeyakul; L Q Guo; K Fukuda; T Ohta; Y Yamazoe
Journal:  Arch Biochem Biophys       Date:  2000-06-15       Impact factor: 4.013

8.  Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes.

Authors:  Yuan Hua Wen; Jasminder Sahi; Ellen Urda; Shaila Kulkarni; Kelly Rose; Xianxian Zheng; Jacqueline F Sinclair; Hongbo Cai; Stephen C Strom; Vsevolod E Kostrubsky
Journal:  Drug Metab Dispos       Date:  2002-09       Impact factor: 3.922

9.  Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6.

Authors:  Hsia-lien Lin; Haoming Zhang; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-01-23       Impact factor: 4.030

10.  tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance.

Authors:  Haoming Zhang; Hsia-lien Lin; Vyvyca J Walker; Djemel Hamdane; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-08-31       Impact factor: 4.436

View more
  17 in total

1.  Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Authors:  Sara K Quinney; Srikar R Malireddy; Raj Vuppalanchi; Mitchell A Hamman; Naga Chalasani; J Christopher Gorski; Stephen D Hall
Journal:  Eur J Clin Pharmacol       Date:  2012-07-10       Impact factor: 2.953

Review 2.  Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.

Authors:  Han Kiat Ho; James Chun Yip Chan; Klarissa D Hardy; Eric Chun Yong Chan
Journal:  Drug Metab Rev       Date:  2015-02-02       Impact factor: 4.518

3.  The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.

Authors:  Hsia-lien Lin; Jaime D'Agostino; Cesar Kenaan; Diane Calinski; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2013-07-25       Impact factor: 3.922

4.  Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.

Authors:  Amanda K Bolles; Rina Fujiwara; Erran D Briggs; Amin A Nomeir; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2014-10-01       Impact factor: 3.922

5.  A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Authors:  Matthew K Matlock; Abhik Tambe; Jack Elliott-Higgins; Ronald N Hines; Grover P Miller; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2019-07-29       Impact factor: 3.739

6.  A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2.

Authors:  Jiawang Liu; Peter T Pham; Elena V Skripnikova; Shilong Zheng; La'nese J Lovings; Yuji Wang; Navneet Goyal; Sydni M Bellow; Lydia M Mensah; Amari J Chatters; Melyssa R Bratton; Thomas E Wiese; Ming Zhao; Guangdi Wang; Maryam Foroozesh
Journal:  J Med Chem       Date:  2015-08-10       Impact factor: 7.446

Review 7.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

8.  Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction tool.

Authors:  Xue Fen Koe; Tengku Sifzizul Tengku Muhammad; Alexander Shu-Chien Chong; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Food Sci Nutr       Date:  2014-06-10       Impact factor: 2.863

9.  Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions.

Authors:  Avanthika Venkatachalam; Abhinav Parashar; Kelath Murali Manoj
Journal:  In Silico Pharmacol       Date:  2016-02-19

10.  The Distribution of Coumarins and Furanocoumarins in Citrus Species Closely Matches Citrus Phylogeny and Reflects the Organization of Biosynthetic Pathways.

Authors:  Audray Dugrand-Judek; Alexandre Olry; Alain Hehn; Gilles Costantino; Patrick Ollitrault; Yann Froelicher; Frédéric Bourgaud
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.